Celon Pharma SA

Celon Pharma's capital structure is characterized by a low debt-to-equity ratio of 0.05, indicating a conservative leverage profile. The company maintains a current ratio of 1.68, suggesting it has sufficient short-term assets to cover its liabilities. However, the company reported negative free cash flow of -63.395 million PLN, driven by capital expenditures of -32.871 million PLN. The liquidity risk is assessed as low, with no immediate filing-based liquidity flags detected. Profitability metrics show a challenging performance, with a return on equity of -21.53% and a return on assets of -17.24%. These figures are below the typical expectations for the pharmaceutical industry, which generally sees positive returns due to high-margin product offerings. The company reported a net loss of 78.43 million PLN and an operating loss of 58.686 million PLN, indicating significant operational challenges. Celon Pharma's revenue is concentrated in its core pharmaceuticals business, with no disclosed geographic diversification in the provided data. The company's product portfolio includes a range of pills and inhalation powders, but the financial snapshot does not provide segment-specific revenue details. The company's exposure to specific therapeutic areas such as oncology and neurology is a strategic focus, but the financial performance in these areas is not quantified. The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the outlook. The operating cash flow of 22.039 million PLN contrasts with the negative net income, suggesting potential non-cash expenses or asset write-downs. The capital expenditures indicate ongoing investment in infrastructure, but the negative free cash flow suggests that these investments are not yet generating positive returns. Risk factors include the company's current financial losses and the potential for future dilution, although the dilution risk is assessed as low. The company has not issued additional shares recently, and there are no immediate filing-based dilution flags. The conservative capital structure and low debt levels provide some buffer against financial distress, but the negative returns on equity and assets remain a concern. Recent events include the disclosure of financial results showing a net loss and operating loss. Analysts have provided a mean price target of 18.57 PLN, with a median of 18.00 PLN, and a mean recommendation of 3.20, indicating a cautious outlook. There are no strong buy recommendations, with one buy and two hold ratings.